Amgros Awards DKK 690 Million Pharmaceutical Framework

Amgros I/S has awarded a DKK 690 million framework agreement for pharmaceutical products to multiple suppliers including FrostPharma AB, Zentiva Denmark ApS, Sun Pharmaceuticals Germany GmbH, and Devatis GmbH. The four-lot framework covers Bortezomib, Thalidomid, Lenalidomid, and Pomalidomid for Danish hospital pharmacies from January 2027.

Introduction

Ensuring the supply of essential medicines to hospital pharmacies is a critical function of Denmark's healthcare system. Amgros I/S, the central purchasing body for the five Danish regions, conducts competitive procurements to secure cost-effective pharmaceutical products for hospital pharmacies across the country.

This framework, valued at up to DKK 690 million (approximately €92.5 million), covers four lots for key pharmaceutical products: Bortezomib (Lot 1), Thalidomid (Lot 2), Lenalidomid (Lot 3), and Pomalidomid (Lot 4). The contracts, running from January 2027, have been awarded to FrostPharma AB, Zentiva Denmark ApS, Sun Pharmaceuticals Germany GmbH, and Devatis GmbH.

This procurement ensures that Danish hospital pharmacies have access to essential medicines for cancer treatment and other serious conditions.

Why This Contract Matters

Cancer treatment relies on a range of essential medicines, including immunomodulatory agents like Lenalidomid and Pomalidomid. This framework ensures the supply of these critical medicines to Danish hospital pharmacies.

This contract matters because it:

• Secures essential medicines: Covers Bortezomib, Thalidomid, Lenalidomid, and Pomalidomid
• Supports cancer treatment: Medicines for multiple myeloma and other cancers
• Serves Danish hospitals: Supplies hospital pharmacies across all five regions
• Significant value: DKK 690 million (approx. €92.5 million)
• Price-focused: Price-only evaluation (100%)
• Competitive process: 2-6 bids per lot
• International suppliers: Winners from Sweden, Denmark, and Germany

Contract Timeline

• Contract award notice published: 12 August 2026 (OJ S 154/2026)
• Previous notice referenced: 219057-2026
• Contract concluded: 11 August 2026
• Coverage start date: 1 January 2027
• Coverage end date: 31 December 2028 (with 12-month extension option)

Contract Overview

Amgros I/S conducted an open procedure for this procurement. The framework covers pharmaceutical products across four lots, each representing a separate sub-contract.

Key features include:

• Four lots: Bortezomib, Thalidomid, Lenalidomid, Pomalidomid
• Total maximum value: DKK 690,479,003 (approx. €92.5 million)
• Duration: 1 January 2027 – 31 December 2028 (with 12-month extension option)
• Evaluation: Price only (100%)
• Framework type: Without reopening of competition
• Non-exclusive: Hospital pharmacies are not obligated to use the framework
• Delivery: Nationwide across all Danish regions

Key Contract Details

Detail	Information
Contracting authority	Amgros I/S
Winning bidders	FrostPharma AB (Lot 1), Zentiva Denmark ApS (Lot 2), Sun Pharmaceuticals Germany GmbH (Lot 3), Devatis GmbH (Lot 4)
Contract subject	Pharmaceutical products (CPV 33600000)
Procedure type	Open procedure
Legal basis	EU Directive 2014/24/EU
Total maximum value (DKK)	DKK 690,479,003.00 (approx. €92.5 million)
Lot 1 (Bortezomib) value	DKK 53,393,487
Lot 2 (Thalidomid) value	DKK 1,611,360
Lot 3 (Lenalidomid) value	DKK 437,861,613
Lot 4 (Pomalidomid) value	DKK 197,612,543
Contract duration	1 Jan 2027 – 31 Dec 2028 (+ 12-month option)
EU funding	None
Covered by GPA	Yes
Evaluation criteria	Price only (100%)
Subcontracting	No

Project Scope

The framework covers four pharmaceutical products for Danish hospital pharmacies:

Lot 1: Bortezomib (FrostPharma AB)

• ATC Code: L01XG01
• Generic name: Bortezomib
• Form: Injection solution
• Strength: 2.5 mg/ml
• Estimated value: DKK 53,393,487
• Units: 16,051
• Bids received: 3

Lot 2: Thalidomid (Zentiva Denmark ApS)

• ATC Code: L04AX02
• Generic name: Thalidomid
• Form: Capsules
• Strength: 50 mg
• Estimated value: DKK 1,611,360
• Units: 2,492
• Bids received: 2

Lot 3: Lenalidomid (Sun Pharmaceuticals Germany GmbH)

• ATC Code: L04AX04
• Generic name: Lenalidomid
• Form: Capsules
• Strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg
• Estimated value: DKK 437,861,613
• Units: 287,033 (various strengths)
• Bids received: 4

Lot 4: Pomalidomid (Devatis GmbH)

• ATC Code: L04AX06
• Generic name: Pomalidomid
• Form: Capsules
• Strengths: 1 mg, 2 mg, 3 mg, 4 mg
• Estimated value: DKK 197,612,543
• Units: 43,407 (various strengths)
• Bids received: 6

About the Contracting Authority

Amgros I/S is a Danish joint procurement body (interessentskab) owned by the five Danish regions. Amgros is responsible for purchasing pharmaceuticals and medical equipment for the Danish hospital sector. As a central purchasing body, Amgros negotiates framework agreements that are available to hospital pharmacies across Denmark, as well as for resale to the Faroe Islands and Greenland. The organisation is based in Copenhagen.

About the Winning Companies

FrostPharma AB (Lot 1 – Bortezomib)

FrostPharma AB is a Swedish pharmaceutical company based in Danderyd, Stockholm. The company specialises in the supply of generic and specialty pharmaceuticals. FrostPharma's winning bid of DKK 1,250,000 was the successful tender among three bids received.

Zentiva Denmark ApS (Lot 2 – Thalidomid)

Zentiva Denmark ApS is a Danish pharmaceutical company based in Frederiksberg, Copenhagen. Zentiva is a leading supplier of generic medicines in Europe. The company won Lot 2 with a bid of DKK 754,000.

Sun Pharmaceuticals Germany GmbH (Lot 3 – Lenalidomid)

Sun Pharmaceuticals Germany GmbH is a German subsidiary of Sun Pharma, one of the world's largest generic pharmaceutical companies. Based in Leverkusen, the company specialises in oncology and specialty medicines. Sun Pharma's winning bid of DKK 2,100,000 was the successful tender among four bids received.

Devatis GmbH (Lot 4 – Pomalidomid)

Devatis GmbH is a German pharmaceutical company based in Lörrach, Baden-Württemberg. The company specialises in oncology and specialty pharmaceuticals. Devatis won Lot 4 with a bid of DKK 1,170,000, competing against five other bidders.

Procurement Analysis

• Procedure: An open procedure was used, allowing any interested economic operator to submit a tender.
• Competition: Competition varied by lot, with 2-6 bids received. Lot 4 (Pomalidomid) attracted the most bids (6).
• Evaluation criteria: Price only (100%). This is standard for pharmaceutical procurement, where quality is assured through regulatory compliance.
• International participation: Bids were received from Sweden, Denmark, and Germany, demonstrating the European nature of the pharmaceutical market.
• SME participation: All bidders were SMEs (micro, small, or medium enterprises), reflecting the structure of the pharmaceutical supply market.
• Non-exclusive framework: Hospital pharmacies are not obligated to use the framework, providing flexibility.
• Options: Pre- and post-agreement period options provide flexibility.

Additional Procurement Facts

• The contract is covered by the WTO's Government Procurement Agreement (GPA).
• No EU funds were used for this procurement.
• The procurement was not accelerated.
• No dynamic purchasing system was used.
• Framework agreements without reopening of competition were used.
• Bids received from Sweden, Denmark, and Germany.
• All bidders were SMEs.
• No subcontracting was declared by any winner.
• Disputes or review requests fall to Klagenævnet for Udbud (Danish Complaints Board for Procurement).
• Delivery locations include hospitals and hospital pharmacies across all Danish regions.

Market & Industry Perspective

The Danish pharmaceutical market is characterised by competitive procurement through Amgros, which leverages the collective buying power of the five Danish regions. The market for oncology pharmaceuticals is particularly competitive, with multiple generic suppliers offering products.

Key trends in this market include:

• Generic competition: Generic versions of oncology drugs provide cost savings
• Price focus: Price-only evaluation drives competition
• International suppliers: Suppliers from across Europe compete for Danish contracts
• SME participation: SMEs dominate the pharmaceutical supply market
• Centralised procurement: Amgros centralises procurement for efficiency

Economic Significance

At DKK 690 million (approximately €92.5 million), this framework represents a significant procurement for Danish hospital pharmacies. The contract ensures:

• Supply security: Essential medicines for cancer treatment are secured
• Cost efficiency: Competitive procurement drives down costs
• Patient care: Hospital pharmacies can access essential medicines
• Regional coverage: All five Danish regions are covered

Future Procurement Opportunities

With the framework now in place, future opportunities include:

• Contract extension: 12-month extension option available
• Re-tender: The framework will be re-tendered for 2029 onwards
• Other products: Amgros conducts many other pharmaceutical procurements
• Other European countries: Similar frameworks are conducted by other central purchasing bodies

Opportunities for Suppliers

While this framework is awarded, future opportunities exist for pharmaceutical companies:

• Other Amgros tenders: Amgros conducts many other pharmaceutical procurements
• Other European countries: Similar frameworks by other central purchasing bodies
• New products: Emerging oncology and specialty medicines
• Re-tender: The framework will be re-tendered in the future

What Businesses Should Watch

• Amgros' future procurement notices
• Other European central purchasing bodies' tenders
• Emerging oncology and specialty medicines
• Changes to Danish pharmaceutical regulations
• EU pharmaceutical procurement developments

DenmarkTender Procurement Intelligence

This pharmaceutical framework is a significant procurement for Danish hospital pharmacies. Several features stand out:

• Scale: DKK 690 million across four lots
• Price focus: Price-only evaluation (100%) drives competition
• International competition: Suppliers from Sweden, Denmark, and Germany participated
• SME dominance: All bidders and winners are SMEs
• Oncology focus: All products are essential cancer treatments

For suppliers, this procurement highlights the importance of:

• Competitive pricing: Price is the sole criterion
• Regulatory compliance: Quality is assured through regulatory approvals
• European presence: Ability to supply across borders
• Supply reliability: Dependable delivery to hospital pharmacies

Supplier Takeaways

• Offer competitive pricing—price is the sole criterion (100%)
• Ensure regulatory compliance for pharmaceutical products
• Develop European presence to participate in cross-border tenders
• Demonstrate reliable supply capabilities
• Monitor Amgros and other central purchasing bodies for future opportunities
• Consider SME status as an advantage in this market

Key Takeaways

• Amgros awarded a DKK 690 million pharmaceutical framework
• 4 lots: Bortezomib (FrostPharma), Thalidomid (Zentiva), Lenalidomid (Sun Pharma), Pomalidomid (Devatis)
• Evaluation: Price only (100%)
• 2-6 bids per lot
• Duration: 1 Jan 2027 – 31 Dec 2028 (+ 12-month option)
• All winners are SMEs
• Suppliers from Sweden, Denmark, and Germany
• No EU funding used

Conclusion

This pharmaceutical framework represents a significant procurement for Danish hospital pharmacies, securing essential medicines for cancer treatment from January 2027. By awarding four lots to specialised suppliers—FrostPharma, Zentiva, Sun Pharma, and Devatis—Amgros ensures that Danish hospitals have access to Bortezomib, Thalidomid, Lenalidomid, and Pomalidomid at competitive prices.

The price-only evaluation (100%) drives strong competition, with 2-6 bids per lot. The participation of suppliers from Sweden, Denmark, and Germany demonstrates the European nature of the pharmaceutical market. All winners are SMEs, reflecting the structure of the generic pharmaceutical supply chain.

As Amgros continues to conduct pharmaceutical procurements for the Danish hospital sector, further opportunities will arise for suppliers with competitive pricing and reliable supply capabilities.

Frequently Asked Questions

Q: What is Amgros?

Ans: A Danish joint procurement body (interessentskab) owned by the five Danish regions, responsible for purchasing pharmaceuticals and medical equipment for the hospital sector.

Q: What is the value of the framework?

Ans: DKK 690,479,003 (approximately €92.5 million).

Q: Who are the winners?

Ans: FrostPharma AB (Lot 1), Zentiva Denmark ApS (Lot 2), Sun Pharmaceuticals Germany GmbH (Lot 3), Devatis GmbH (Lot 4).

Q: What products are covered?

Ans: Bortezomib, Thalidomid, Lenalidomid, and Pomalidomid.

Q: What were the evaluation criteria?

Ans: Price only (100%).

Q: How long is the contract?

Ans: 1 January 2027 – 31 December 2028 (with a 12-month extension option).

Q: How many bids were received?

Ans: 2-6 bids per lot.

Q: Is this contract funded by the EU?

Ans: No, the procurement is not financed with EU funds.

Source: EU Official Journal, Contract Award Notice 560003-2026, OJ S 154/2026, published 12 August 2026.